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PARP-1 inhibition has recently been employed in both mono- and combination
therapies in various malignancies including melanoma with both promising and
contradicting results reported. Although deeper understanding of the underlying
molecular mechanisms may help improving clinical modalities, the complex cellular
effects of PARP inhibitors make disentangling of the mechanisms involved in
combination therapies difficult. Here, we used two cytostatic agents used in melanoma
therapies in combination with PARP inhibition to have an insight into cellular events
using the B16F10 melanoma model. We found that, when used in combination with
cisplatin or temozolomide, pharmacologic blockade of PARP-1 by PJ34 augmented
the DNA-damaging and cytotoxic effects of both alkylating compounds. Interestingly,
however, this synergism unfolds relatively slowly and is preceded by molecular events
that are traditionally believed to support cell survival including the stabilization of
mitochondrial membrane potential and morphology. Our data indicate that the PARP
inhibitor PJ34 has, apparently, opposing effects on the mitochondrial structure and
cell survival. While, initially, it stimulates mitochondrial fusion and hyperpolarization,
hallmarks of mitochondrial protection, it enhances the cytotoxic effects of alkylating
agents at later stages. These findings may contribute to the optimization of PARP
inhibitor-based antineoplastic modalities.
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INTRODUCTION
Poly(ADP-ribose) polymerase-1 (PARP-1) catalyzes the transfer
of ADP-ribose from NAD+ to a wide range of target proteins
leading to the formation of large, branching PAR chains
that modulate enzymatic activity, DNA binding or regulatory
properties in gene expression (Jiang et al., 2015; Gibson et al.,
2016). PARP-1 also regulates gene expression by self-ADP-
ribosylation-dependent binding to specific DNA sequences and
by ADP-ribosylation of the PARP-1-CTCF-Dnmt1 complex
that prevents DNA methylation (Zampieri et al., 2012; Gibson
et al., 2016). Increased activation of PARP-1 in oxidative
stress substantially reduces NAD+ levels that contribute to
the compromised energy state and lead to necrotic cell death.
In accordance, PARP inhibitors were found to have dramatic
protective effects in several disease models where necrotic or
apoptotic cell death is a key critical pathological factor (Pacher
et al., 2002; Robaszkiewicz et al., 2012; Gero et al., 2014; Eros et al.,
2017; Korkmaz-Icoz et al., 2018).
The PARP inhibitors were used successfully as monotherapy
of BRCA1/2 mutated cancers, based on the fact that PARP
inhibitions reduce the rate of DNA repair (Bhattacharjee and
Nandi, 2017; Ashworth and Lord, 2018). PARP inhibitors
were also found to facilitate the efficacy of both cytostatic
agents like cisplatin and irradiation (Sakogawa et al., 2013;
Bang et al., 2017; Litton et al., 2018). Considering that
(i) PARP inhibitors were found to protect cells against
oxidative stress-induced cell death and (ii) oxidative stress often
accompanies radio- and chemotherapy, the molecular effects of
PARP inhibitors in the distinct pathological situations remained
obscure (McQuade et al., 2018).
Melanoma is one of the most malignant cancers harboring
defects in repair and cell-cycle regulation. Indeed, it is believed
that melanoma is associated with malfunctioning nucleotide
excision repair and is among the most commonly reported
cancers carrying BRCA2 mutations (Breast Cancer Linkage
Consortium, 1999; Di Lucca et al., 2009; Moran et al., 2012;
Mersch et al., 2015). Because of their observed efficacy in
BRCA-mutated tumors and the role of PARP-1 in cellular repair
mechanisms, PARP inhibitors were introduced into melanoma
therapy (Bryant et al., 2005). In melanomas, PARP inhibitors
promoted cell death in combination with temozolomide both
in vitro and in clinical studies but the underlying mechanism
of action remains to be elucidated (Plummer et al., 2013;
Abbreviations: AKT/PKB, AKT/protein kinase B; ATF4, activating transcription
factor 4; ATM, ataxia telangiectasia mutated; AV, annexin V; BRCA1/2,
breast cancer type 1/2 susceptibility protein; BSA, bovine serum albumin;
FCCP, p-trifluoro-methoxy-phenyl-hydrazone; FITC, fluorescein isothiocyanate;
HBSS, Hank’s balanced salt solution; HEPES, 4-(2-hydroxyethyl)-1-piperazine-
ethane sulfonic acid; L-OPA1, long isoforms of OPA1; MAP kinases, mitogen-
activated protein kinase; MAPK, mitogen-activated protein kinase; MKP-1,
mitogen-activated protein kinase phosphatase 1; mTOR, mammalian target of
rapamycin; NAD+, nicotinamide-adenine-dinucleotide; NADPH, nicotinamide
adenine dinucleotide phosphate; NEMO, NF-kappa-B essential modulator; OPA1,
dynamin-like 120 kDa mitochondrial protein; PAR, Poly(ADP-ribose); PAR,
poly(ADP-ribose) polymers; PARP, Poly(ADP-ribose) polymerase; PI, propidium
iodide; PI-3K-AKT, phosphatidylinositol-3-kinase and protein kinase B; S-OPA1,
short isoforms of OPA1; TBST, Tween-20 containing tris-buffered saline; TMRM,
tetramethyl-rhodamine methyl ester.
Gill et al., 2015; Middleton et al., 2015). To have a further
insight into the role of PARP inhibition in combination
therapy, we investigated the effects of the PARP inhibitor PJ34
when applied in combination with cisplatin or temozolomide
using the B16F10 in vitro melanoma model. We found
that PARP-inhibition exerts complex, apparently opposing,
effects on cellular physiology. Indeed, while pharmacologic
PARP-inhibition triggers mitochondrial processes that are known
to be associated with cell survival, it also potentiates the cytotoxic
effects of cytostatic compounds in B16F10 cells. This dichotomy
may, at least in part, provide explanation to the controversial
clinical observations upon the use of pharmacologic PARP
inhibition as part of anti-neoplastic interventions.
MATERIALS AND METHODS
Reagents
Chemicals were purchased from (Sigma-Aldrich S.r.l., Milan,
Italy) unless otherwise stated. The PARP inhibitor compound
PJ34, temozolomide and cisplatin were used at 10, 25, and
25 µM concentrations, respectively. The mitochondrial targeted
dsRED (mtRFP) corresponding to pDsRed2-Mito and the
pPARPGFPC1/N3 construct has been previously described in
Cipolat et al. (2004) and Tapodi et al. (2005), respectively.
Cells and Cell Cultures
Mouse B16F10 melanoma cell line was obtained from American
Type Culture Collection (Manassas, VA, United States) and
maintained in Dulbecco’s Modified Eagle Medium (Invitrogen,
Life Technologies, Milan, Italy) supplemented with 10% (v/v)
fetal bovine serum (Thermo Fisher, Life Technologies, Milan,
Italy), 1% (v/v) penicillin/streptomycin and glutamine mixture
(Invitrogen, Life Technologies, Milan, Italy). Transiently
transfected B16F10 cells were generated using Transfectin Lipid
Reagent (Bio-Rad Laboratories S.r.l., Milan, Italy) according
to the manufacturer’s instructions. After 4–6 h of incubation,
the medium was replaced to complete culture medium and the
experiments were performed 24 h post-transfection.
MTT Assay
Cells were seeded in flat-bottom 96-well plates at the
2.5 × 104 per well density and cultured overnight before
the assay. Following treatments, medium was replaced to a
fresh one containing 0.5% 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) tetrazolium substrate
and incubated for 3 h. The water-insoluble violet formazan
precipitate was solubilized in 100 µl 20% sodium dodecyl
sulfate solution and optical densities were measured by an
Infinite 200 Pro plate reader (Tecan Italia S.r.l., Milan, Italy) at
570 nm. All experiments were run at least in four parallels and
repeated three times.
Clonogenic Cell Survival Assay
Cells were plated in 6-well plates at 300 cells/well density and
cultured overnight before treatments and incubated for 10 days
post-treatment. Following the incubation period, cells were
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washed with 1 × PBS and stained with 0.1% Coomassie blue
(Bio-Rad Laboratories S.r.l., Milan, Italy) in 30% methanol and
10% acetic acid. Plates were scanned and the number of colonies
was determined using the ImageJ software.
Analysis of Cell Death
B16F10 cells were seeded into 6-well plates at a starting density of
2× 104cell/well and cultured for 24 h before treatments. Samples
were stained with FITC-labeled Annexin-V and Propidium
iodide (eBioscience, Life Technologies, Milan, Italy) according
to the manufacturer’s protocol. Cell death was measured by
flow cytometry using a FACS Calibur flow cytometer (Becton
Dickinson Italia S.r.l., Milan, Italy), and the data were analyzed
by CellQuest Pro software.
Modified Alkaline Single Cell Gel
Electrophoresis (Comet Assay)
Microscope slides were coated with a layer of 1% normal
melting point agarose in PBS. B16F10 cells were seeded into
6-well plates at a starting density of 7 × 104 cell/well. After
treatment, cells were harvested, centrifuged, and mixed rapidly
with 500 µl of 1% pre-warmed low melting point agarose in
PBS. 50 µl suspension was pipetted onto the pre-coated slides
and kept at 4◦C for 10 min. Slides were incubated in lysis
solution (2.5 M NaCl, 300 mM Tris, 200 mM NaOH, 3 mM
Na2EDTA, 1% Triton X-100) for 15 min and electrophoresed
at 25 V and 300 mA at 4◦C for 30 min. Slides were
neutralized three times for 5 min using Tris buffer (0.58 M,
pH 7.5) and immersed in 70% ethanol for 5 min. Slides were
stained with 0.25 µg/ml Hoechst 33342 for 10 min, washed
two times in PBS and visualized by a Nikon Eclipse Ti-U
fluorescent microscope equipped with a Spot RT3 camera
using a 60× objective lens. At least 25 cells were randomly
selected and analyzed. Comet attributes were analyzed using
ImageJ 1.43f software.
Analysis of Nuclear Fragmentation
2,000 cells/well were seeded in 96-well plates and cultured
overnight before treatments. Following treatments, the cells
were washed with 1 × PBS and incubated with 0.5 µg/ml
Hoechst 33342 for 10 min. Nuclei were visualized by a Nikon
Eclipse Ti-U fluorescence microscope equipped with a Spot
RT3 camera using 4× and 20× objective lenses. Images were
recorded using a 4× objective lens. Nuclei having condensed
or fragmented apoptotic characteristics were quantified using
the ImageJ software (NIH). For each treatment, at least 300
nuclei were evaluated.
Analysis of Mitochondrial Morphology
Mitochondrial morphology of B16F10 cells transfected
with pDsRed2-Mito either alone or in combination with
pPARPGFPC1/N3 construct were analyzed by confocal
microscopy. Confocal Z-stacks were acquired using an
IMIC Andromeda system (Fondis Electronic) equipped
with a 60× oil immersion objective (UPLAN 60× oil,
1.35NA, Olympus, Milan, Italy) at 488 and 561 nm excitation
wave lengths using HC 525/39 and HC 615/20 (Semrock)
emission filters. Length of mitochondria was determined
by measuring 10 mitochondria per cell manually using
the ImageJ software (NIH). In each sample, at least 20
cells were analyzed.
Tetramethyl-Rhodamine Methyl Ester
(TMRM) Time-Laps Fluorescence
Imaging
Cells were incubated in 10 nM TMRM [dissolved in Hank’s
Balanced Salt Solution (HBSS)] supplemented with 10 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), in
the presence of 1 µM P-glycoprotein inhibitor cyclosporine
H in 5% CO2 atmosphere at 37◦C for 30 min as previously
described in Frezza et al. (2006). Sequential images of
TMRM fluorescence were acquired every 60 s using the
aforementioned IMIC Andromeda system for 30 min. As
for depolarization control, 2 µM oligomycin and 2.5 µM
carbonyl cyanide p-trifluoro-methoxyphenyl hydrazone (FCCP)
were added at 5 and 25 min post-treatment, respectively.
Analyses of the TMRM fluorescence of the mitochondrial
regions of interest were carried out using the ImageJ software
(NIH). Data are expressed as average ±SEM of at least 3
independent experiments.
Immunoblot Analysis
B16F10 cells were harvested in cold RIPA lysis buffer
complemented with 1% protease inhibitor cocktail and
10% Phos-stop phosphatase inhibitor mixture (Roche,
Sigma-Aldrich S.r.l., Milan, Italy), incubated on ice for
30 min and centrifuged at 10,000 g, at 4◦C for 15 min.
Protein concentration was determined using Bradford reagent
(Bio-Rad Laboratories S.r.l., Milan, Italy). Proteins (20 µg/lane)
were separated on Tris-acetate 3–8% or Bis-Tris 4–12%
(NuPAGE, Life Technologies, Milan, Italy) polyacrylamide
gels (Life Technologies, Milan, Italy) and transferred to PVDF
membranes (Merck, Sigma-Aldrich S.r.l., Milan, Italy) that
were blocked in 5% Bovine Serum Albumin (BSA) diluted
in 0.1% Tween-20 containing tris-buffered saline (TBST)
at room temperature for 1 h. Primary antibodies against
OPA1 (Becton Dickinson Italia S.r.l., Milan, Italy, 1:1000),
β-Actin (Sigma-Aldrich S.r.l. Milan, Italy 1:10 000), PAR
(Santa Cruz Biotechnology, 1:500) were incubated in 5%
BSA containing TBST. Horseradish peroxidase-conjugated
anti-rabbit, anti-mouse or anti-rat (Bio-Rad Laboratories S.r.l.,
Milan, Italy) secondary antibodies were diluted in 1:3000 in 5%
milk containing TBST and membranes were incubated at room
temperature for 1 h. Peroxidase labeling was visualized using
enhanced chemiluminescence substrate (Life Technologies,
Pierce, Milan, Italy) and detected by an Image Quant mini
Luminescent Image Analyzer 4000 (GE Healthcare Italia
S.r.l., Milan, Italy).
Statistical Analysis
Data were analyzed by one-way ANOVA with
Tukey post hoc comparison tests with alpha = 0.05;
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n ≥ 3. Significance was expressed as ∗p < 0.05,
∗∗p< 0.01, ∗∗∗p< 0.001.
RESULTS
Effect of PJ34 and Cisplatin or
Temozolomide on Viability, Colony
Formation and Nuclear Fragmentation of
B16F10 Melanoma Cells
It has been reported in various tumor models that cisplatin
and temozolomide have enhanced cytotoxicity when used in
combination with pharmacologic PARP inhibitors (Calabrese
et al., 2004; Donawho et al., 2007). In order to investigate the
putative combined effects of PJ34 and cisplatin or temozolomide
on cellular viability, we performed flow cytometry using
Annexin-VFITC and propidium iodide labeling in B16F10
melanoma cells (Figures 1A–H and Supplementary Figure
S1). We found that neither the alkylating agents nor PJ34
showed cytotoxicity in B16F10 cultures within the first
24 h of treatment (Figures 1A,B). At 48 h post-treatment,
PJ34 developed a mild, although statistical not significant,
cytotoxicity (Figure 1C) that was further increased at 72 h
post-treatment (Figure 1D). A similar trend was observed
with cisplatin that significantly decreased the viability at 72 h
post-treatment (Figure 1D). This effect, however, became
more pronounced when cisplatin was used in combination
with PJ34 for 48 and 72 h (Figures 1C,D). In contrast
to cisplatin, temozolomide did not induce cytotoxicity in
B16F10 cultures (Figures 1A–D). In combination with PJ34,
however, decreased viability was detected 72 h post-treatment,
although it was not statistically significant compared to PJ34
alone (Figure 1D).
Over the first 4 h of treatment, the proportion of apoptotic
(Annexin V positive) and necrotic (propidium iodide positive)
species were not affected by any of the treatments (Figure 1E
and Supplementary Figure S1). After 24 h, apoptosis tended
to dominate (Figure 1F), although this effect did not reach the
level of statistical significance. After 48 h, co-treatment with PJ34
and cisplatin caused significant increase in the abundance of
Annexin V-positive cells (Figure 2G). 72 h post-exposure, all
substances but temozolomide increased apoptosis significantly;
in combination in a more pronounced way than alone
(Figure 1H). We did not observe any significant change in
necrosis (Supplementary Figure S1).
In order to evaluate the cytostatic effects of PJ34, cisplatin
and temozolomide on B16F10 melanoma cells, we performed
colony formation assays to observe cellular proliferation capacity
(Figures 1I,J). We found that, unlike temozolomide, both
PJ34 and cisplatin decreased colony formation in B16F10
cultures. This effect was more evident in cisplatin-treated
cultures where the number of colonies was reduced by
more than 60% at 10 days post-treatment. Temozolomide
alone did not affect B16F10 colony formation, however,
it reduced colony formation in combination with PJ34
moderately (Figures 1I,J).
In order to study the potential underlying mechanisms,
we analyzed the DNA-damaging effects of the compounds
used. B16F10 cells were exposed to cisplatin, temozolomide
or PJ34 in different combinations and alkaline single cell
gel electrophoresis assay was performed on at least 25
randomly selected cells in each treatment cohorts. We found
that all compounds examined triggered DNA fragmentation
(Figures 2A–D). Temozolomide-treated cells accumulated DNA
breaks in comparable extent to that of PJ34 but they were less
effective than cisplatin alone. Combination of the pharmacologic
PARP inhibition with cisplatin or temozolomide, however,
led to increased number of persisting DNA-breaks and this
augmenting effect of PJ34 was more pronounced in combination
with temozolomide. These data are in accordance with our
cytotoxicity and colony formation assay results and support
the idea of the existence of a synergistic effect between PARP
inhibition and alkylating compounds in B16F10 cells.
In order to confirm the presence of elevated apoptosis, we
quantified the number of apoptotic nuclei in B16F10 cells treated
with cisplatin, temozolomide either alone or in combination
with PJ34 (Figures 2E–H). We found that, unlike temozolomide
and PJ34, cisplatin triggered apoptotic nuclear morphology
promptly in B16F10 cells. Surpisingly, this effect was not
increased any further by the use of PJ34 during the first 24 h of
the treatments (Figure 2F). In contrast, combinatorial treatment
with PJ34 and temozolomide resulted in significantly more
apoptotic nuclei than that of the standalone temozolomide
treatment (Figure 2F). More interestingly, 48 h post-treatment,
PARP inhibition increased the number of apoptotic nuclei,
an effect that was more pronounced in combination with
cisplatin (Figure 2H).
Taken together, flow cytometry and nuclear morphology
data indicate distinct kinetic of the cisplatin- and
temozolomide-induced cytotoxicity in B16F10 cells. Unlike
cisplatin that provoke a prominent early apoptotic response,
the cytotoxic effect of temozolomide unfolds gradually.
PJ34-mediated pharmacologic inhibition of PAPR-1 enhances
the cytotoxic effect of both cisplatin and temozolomide and this
effect was accompanied by hallmarks of apoptosis including
elevated Annexin V binding and apoptotic nuclear morphology.
The augmenting effect of PJ34, however, develops slower and
requires 48 h to become significant.
Effect of PJ34 and Cisplatin or
Temozolomide on Mitochondrial
Fragmentation in B16F10 Cells
A number of studies proposed a model that the cytotoxic
effect of cisplatin is, at least in part, mediated by mitochondria
(Gordon and Gattone, 1986; Rosen et al., 1992; Olivero et al.,
1995; Yang et al., 2006). Interestingly, mitochondria have also
been suggested as target of pharmacologic PARP inhibition
raising the question whether mitochondrial events are involved
in the cytotoxic and cytostatic effects of PJ34, cisplatin, and
temozolomide in the B16F10 melanoma model (Cseh et al.,
2017). In order to investigate this hypothesis, we studied the
integrity of the mitochondrial network using B16F10 cells
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FIGURE 1 | Effect of PJ34 in combination with cisplatin or temozolomide on cytotoxicity and colony formation in B16F10 melanoma cells. Cells were treated as
indicated in the figure, labeled with Annexin VFITC (AV) and propidium iodide (PI) and subjected to flow cytometry. AV and PI double-negative live (A–D) as well as AV
positive apoptotic cells (E–H) are presented as % of all cells after 4 (A,E), 24 (B,F), 48 (C,G), and 72 (D,H) hours of treatment. In a parallel experiment, B16F10 cells
were treated as indicated in the figure and stained with trypan blue after 10 days of incubation. Representative image (I) and quantitative assessment (J) of colony
formation is presented. Values are expressed as mean + SEM, N = 3, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; NS, non-significant.
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FIGURE 2 | Effect of PJ34 on cisplatin and temozolomide-induced cell death and nuclear fragmentation in a B16F10 cells. Comet assay (A–D). Cells were treated
for 4 (A,B) or 24 (C,D) hours as indicated in the figure and a modified alkaline single cell gel electrophoresis was used to detect DNA damage. At least 25 cells per
treatment group were randomly selected and analyzed. Comet attributes (tail DNA) were analyzed using ImageJ 1.43f software. Results of three independent
experiments are presented as representative images (A,C) and bar diagrams (B,D) of mean + SEM tail DNA values expressed in arbitrary units (a.u.). Nuclear
fragmentation (E–H). Cells were treated as indicated in the figure for 24 (E,F) and 48 (G,H) hours and stained with Hoechst 33342 post-treatment. Panel (E,G)
shows representative micrographs recorded by confocal microscopy. Nuclear morphology was assessed by evaluating a minimum of 300 nuclei per sample using
the ImageJ software. Panel (F,H) shows quantification of the nuclear morphology, measured by the frequency of fragmented nuclei. Arrows indicate Hoechst 33342
stained cells having condensed or fragmented apoptotic nuclei. Values are expressed as mean + SEM, N = 6, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; NS,
non-significant. Scale bar 20 µm.
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FIGURE 3 | Effect of PJ34, cisplatin and temozolomide on mitochondrial fragmentation. B16F10mtRFP cells were treated with cisplatin, temozolomide, PJ34 and
their combinations. Representative reconstructions of confocal z-stacks are shown after 4 (A) 24 (C), and 48 (E) hours post-treatment. Panel (B,D,F) shows
quantification of the mean length of mitochondria at 4, 24-, and 48-h post-treatments, respectively. Values are expressed as mean + SEM, N = 3, ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001, Scale bar: 10 µm.
expressing a mitochondria-directed red fluorescent protein
(B16F10mtRFP) (Figure 3). In accordance with literature data
from other models (Choi et al., 2015), elevated mitochondrial
fragmentation was observed in melanoma cells treated with
cisplatin as early as 4 h post-treatment (Figures 3A,B).
A similarly swift disruption of the mitochondrial network was
observed in temozolomide-treated B16F10 cells (Figures 3A,B).
In contrast, pharmacologic PARP inhibition by PJ34 did not
Frontiers in Physiology | www.frontiersin.org 7 May 2019 | Volume 10 | Article 538
fphys-10-00538 May 4, 2019 Time: 16:55 # 8
Cseh et al. Diverse Effects of PARP Inhibition
affect mitochondrial morphology. Moreover, PJ34 attenuated
the mitochondrial effects of cisplatin and temozolomide
maintaining the hyperfused mitochondrial phenotype when
used in conjunction with the cytostatic compounds. This
mitochondrial effect was found to be stable for at least 48 h
post-treatment (Figures 3E,F).
In order to confirm if the observed mitochondrial effects
of PJ34 are mediated by the blockade of PARylation activity,
B16F10mtRFP cells were transfected with a GFP-tagged peptide
spanning the N-terminal DNA-binding domain of PARP-1
(PARPDN) (Figures 4A–C). PARPDN acts as a dominant
negative PARP competing with endogenous PARPs for
PARP recognition loci without exerting PARylation activity.
PARPDN-transfected B16F10mtRFP cells were treated with
cisplatin or temozolomide for 4 h and the mitochondrial
structures were assessed as above (Figures 4A–C). We
found that ectopic expression of PARPDN did not affect
morphology of the mitochondrial network in the absence of
alkylating agents. Down-regulation of the endogenous PARP
activity by PARPDN, however, attenuated the mitochondrial
fragmentation triggered by both cisplatin and temozolomide
supporting the concept that the mitochondrial effects
of PJ34 are mediated by the reduction of endogenous
poly(ADP-ribosyl)ation.
In order to investigate the potential underlying mechanisms
of the PJ34 protective effects on mitochondrial morphology,
we studied the nuclear encoded Dynamin-like 120 kDa
mitochondrial protein OPA1, one of the key regulators of
mitochondrial dynamics (Ishihara et al., 2006). OPA1 is expressed
as long and short isoforms (L-OPA1 and S-OPA1, respectively)
in mitochondria and both are believed to be critical for
proper mitochondrial fusion, integrity of cristae junctions
(Frezza et al., 2006; Song et al., 2007) and susceptibility to
Cytochrome C release to engage apoptosis (Frezza et al.,
2006). Since balanced expression of OPA1 isoforms promotes
mitochondrial fusion, we raised the question whether the
PJ34-mediated blockade of PARylation impacts the ratio of
the OPA1 isoforms.
To address this question, we performed immunoblot analyses
for OPA1 isolated from B16F10 cells treated with cisplatin
or temozolomide in the presence or absence of PJ34. To
monitor the efficacy of the PJ34 treatment, cell lysates were
also tested for the presence of PAR polymers (Figure 5). We
found no differential expression of either the short or the
L-OPA1 in first 24 h post-treatment (Figures 5A1,A2,B1,B2).
In contrast, an increase of S-OPA1 was detected in melanoma
cells treated with PJ34 in combination with cisplatin for
48 h (Figures 5C1,C2). A similar trend was observed for
PJ34 in combination with temozolomide, although the
densitometry data was not statistically significant. Taken
together, marked accumulation of S-OPA1 was only detected
in cells treated with both PJ34 and cisplatin, and to a lesser
extent temozolomide, for 48 h when combination treatments
rather favors fusion of mitochondria (Figures 3E,F). Since
accumulation of S-OPA1 does not correlate with the observed
morphological deterioration of the mitochondrial network,
these data suggest that the cisplatin-, temozolomide- and
PJ34-related morphological mitochondrial effects are not
mediated by OPA1.
Effect of PJ34 and Cisplatin or
Temozolomide on Mitochondrial
Membrane Potential
Mitochondrial morphology is believed to be intimately connected
to mitochondrial function and metabolism. Indeed, it was
reported that reduction of the electrochemical potential
across the inner mitochondrial membrane is accompanied by
cleavage of L-OPA1 leading to accumulation of S-OPA1 and
mitochondrial fragmentation (Duvezin-Caubet et al., 2006;
Ishihara et al., 2006; Song et al., 2007). Since human melanoma
xenografts have been reported to have one of the highest
oxygen consumption rates among tumors, it is believed that
an intact mitochondrial metabolism is critical for the survival
of melanoma cells (Kallinowski et al., 1989; Barbi de Moura
et al., 2012). In order to investigate whether the cisplatin,
temozolomide and PJ34-mediated effects on mitochondrial
morphology are associated with functional alterations, we
assessed the mitochondrial respiratory chain by measuring
the mitochondrial membrane potential (ψm) (Figure 6).
In order to study the functionality of the mitochondrial
respiratory chain, membrane potential was monitored in
cells treated with the ATP synthase inhibitor oligomycin. For
positive control, depolarization of the mitochondrial inner
membrane was triggered by the mitochondrial uncoupler
carbonyl cyanide p-trifluoro-methoxyphenyl hydrazone
(FCCP). We found that neither cisplatin nor temozolomide
affected the ψm. PJ34 did not influence the mitochondrial
membrane potential either. Interestingly, when PJ34 was used
in combination with the cytostatic agents, we did not detect
the collapse of the mitochondrial membrane potential either
(Figures 6A–C,G–I). Instead, a slight, although statistically not
significant, trend of membrane hyperpolarization was seen. Even
more surprisingly, this trend unfolded more promptly in the
presence of temozolomide compared to cisplatin (Figures 6A–C).
In order to confirm the PARylation dependency of the observed
mitochondrial membrane hyperpolarization, we repeated the
above experiments using cells transfected with a dominant
negative mutant of PARP-1 (PARPDN). Expression of PARPDN
alone did not influence the mitochondrial membrane potential.
In contrast, however, robustly elevated mitochondrial membrane
potential was measured in the PARPDN expressing B16F10 cells
treated with cisplatin or temozolomide (Figures 6D–F). These
data suggest that the cytotoxic effect observed in B16F10 cells
exposed to both PJ34 and the cytostatic agents is not mediated by
the collapse of the mitochondrial membrane potential.
To further investigate the potential interplay between the
PJ34-mediated enhancement of the alkylating agents cytotoxic
effects, we also tested functionality of the mitochondrial
NADPH reducing system performing MTT assays in cells
treated with combinations of PJ34, cisplatin, and temozolomide.
In accordance with our observations on the mitochondrial
membrane potential, however, we did not find any difference
in the activity of the mitochondrial NADPH reductases in the
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presence of PJ34 (Supplementary Figure S2). Taken together,
our data suggest that the mitochondrial and cytotoxic effects of
PJ34 do not correlate and reflects on parallel but independent
molecular mechanisms.
DISCUSSION
Platinum agent-based chemotherapy has been in the clinical
practice for decades in various types of human neoplasms.
Traditionally, it is believed that their mechanism of action is
based on the formation of nuclear platinum-DNA adducts that
lead to DNA-damage, cell-cycle arrest and, eventually, apoptosis
(Rosenberg et al., 1965; Takahara et al., 1995). Accordingly,
they likely provoke an excess rate of the cellular DNA-damage
response that may also contribute to their cytotoxic effect
via, at least in part, PARP-mediated functions (Kelland, 2007;
Thomadaki and Scorilas, 2007). The idea of the interplay between
PARylation and cisplatin has been proposed in the early 1990s on
the basis of the central role of PARP-1 in the nuclear DNA repair
mechanisms termed DNA damage response (Burkle et al., 1993).
This concept is in accordance with observations on PARP
expression in human neoplasms that show elevated PARP-1
expressions in a wide range of human cancers including
high-grade astrocytomas, colorectal carcinomas, hepatocellular
carcinomas or malignant breast lesions (Rojo et al., 2011; Li
et al., 2017; Murnyák et al., 2017; Dörsam et al., 2018). These
studies have also pointed out that increased PARP-1 levels are,
apparently, associated with high-grade tumors and show inverse
correlation with patient survival fueling the idea of the use of
FIGURE 4 | Effect of PARPDN, cisplatin and temozolomide on mitochondrial fragmentation. B16F10 cells were co-transfected with either mtRFP and an empty
vector (EV) (A,C) or mtRFP and pPARPGFPC1/N3 (B,C), treated as indicated in the figure for 4 h and the lengths of mitochondria were quantified. Panel (A,B) show
representative reconstructions of confocal z-stacks while (C) displays the quantification of the mean length of mitochondria at 4-h post-treatments. Values are
expressed as mean + SEM, N = 3, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Scale bar: 10 µm.
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PARP-1 as a prognostic marker and therapeutic target (reviewed
in Cseh et al., 2017).
The finding that PARP-1 promotes human primary
melanocyte proliferation in a PARylation-independent
manner mediated by the induction of the melanocyte-lineage
survival oncogene MITF suggest a universal role of PARP-1
in carcinogenesis supporting the concept of PARP inhibition
as an anti-cancer modality (Choi et al., 2017). Indeed, PARP
inhibition efficiently reduced the metastasizing capacity of
melanoma cells in murine models (Rodriguez et al., 2013).
The potential use of PARP inhibition in human melanomas
has been further supported by a recent retrospective cohort
study of 66 patients with metastatic melanoma treated with
conventional chemotherapy using DNA alkylating compounds
(Abecassis et al., 2019). Data evaluation revealed that the
response to conventional chemotherapy inversely correlates
with the expression of the endogenous PARP-1 variant carrying
a single nucleotide polymorphism termed rs1805407 (SNP
rs1805407). The observation that the use of ABT-888 and
olaparib, two well-known PARP-inhibitors, improved the efficacy
of chemotherapeutics on cancer cells carrying SNP rs1805407
suggests that this variant is associated with higher PARP-1
expression and supports the idea of potential synergism between
conventional therapeutics and pharmacologic PARP inhibition
in the treatment of melanoma.
In the present study, we investigated the effects of two
alkylating agents, cisplatin and temozolomide, commonly used
in melanoma treatment and the PARP inhibitor compound PJ34
using the in vitro B16F10 melanoma model. We found a marked
difference between cisplatin and temozolomide toxicity on
B16F10 cells. Cisplatin exerted a slowly developing cytotoxicity
that was statistically significant 72 h post-treatment. In contrast,
temozolomide was found to be inefficient in provoking
significant cell death in B16F10 cultures within the timeframe
investigated. However, PJ34 potentiated the cytotoxicity of both
cisplatin and temozolomide, the combined effect exceeded that
FIGURE 5 | Effect of PJ34 and cisplatin or temozolomide on ratio of short per long OPA1 isoforms in B16F10 cells. Panel (A1,B1,C1) shows representative
immunoblots of PAR and OPA1 from cells treated as indicated in the figure. S-OPA1 and L-OPA1 indicate its short and long isoforms, respectively. β-Actin was used
for loading control. Panel (A2,B2,C2) display densitometry results of corresponding immunoblots. Values are expressed as mean + SEM, N = 3, ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001; NS, non-significant.
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FIGURE 6 | Effect of PJ34 and cisplatin or temozolomide on mitochondrial membrane potential. Wild type (A–C,G–I) and PARPDN-expressing B16F10 cells (D–F)
were treated for 4 h (A–F) and 24 h (G–I), incubated with TMRM and the red fluorescence correlating with the mitochondrial transmembrane potential was
monitored for 30 min. In each experiment, cells were treated with 2 µM oligomycin and 2.5 µM FCCP, 5 and 25 min after the start of measurements, respectively. O,
oligomycin; F, FCCP. Panels (C,F,I) shows percent change in mitochondrial membrane potential post-oligomycin treatments. Data are expressed as mean + SEM,
N = 3, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; NS, non-significant.
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FIGURE 7 | Effects of pharmacologic PARP inhibition in B16F10 melanoma cells. Schematic model on the synergism between the PARP inhibitor PJ34 and
alkylating agent cisplatin and temozolomide. Arrows and blunt-end connector indicate catalyzed activation and inhibition, respectively. Green and red color refer to
pro-survival and cell death-inducing activities, respectively.
of the individual compound and this effect of PJ34 was more
pronounced on temozolomide. Similar observations were made
on nuclear fragmentation, the ratio of apoptotic cells and
inhibition of colony formation. Our findings are in agreement
with those of others on combination of PARP inhibition and
temozolomide (Erice et al., 2015).
Although the underlying mechanism is still to be elucidated,
the observed differences between the synergistic effect of
PARP-inhibition in the presence of cisplatin or temozolomide
may be accounted for their distinct mechanism of action. Indeed,
cisplatin is believed to inhibit proliferation by crosslinking
DNA and induction of DNA breaks eventually leading to,
predominantly, apoptosis (Prestayko et al., 1979). In contrast,
temozolomide alkylates DNA that is repaired by the O6-
alkylguanine DNA alkyl transferase (MGMT). This enzyme is
expressed in a number of cancer cells including the B16F10
melanoma model (Hau et al., 2007; Shih et al., 2016). These data
together with our own and others observations on the efficacy of
PARP inhibition in combination with distinct chemotherapeutics
suggest that the histological background of the target cells should
be considered critical in the design of anti-cancer strategies
applying PARP inhibitors.
Human melanoma xenografts have been reported to
show extremely high oxygen consumption suggesting their
particular dependency on the intact mitochondrial metabolism
(Kallinowski et al., 1989; Barbi de Moura et al., 2012).
Interestingly, intense research on the mechanism of action
of cisplatin has proposed mitochondrial targets as alternative
effectors of cytotoxicity as well (Cullen et al., 2007). Indeed,
mitochondrial swelling, loss of cristae and disruption of the outer
mitochondrial membrane were all observed in cisplatin-treated
cells (Rosen et al., 1992). In accordance with these reports, we
found extensive and robust disintegration of the mitochondrial
network preceding the onset of cytotoxicity in cisplatin-treated
B16F10 cells. A similar but more pronounced effect was observed
in temozolomide-treated cells despite the limited cytotoxicity
of this compound in the melanoma cultures examined. This
finding suggests that unlike the nuclear ones, mitochondrial
effect of temozolomide is not limited by MGMT activity. In
agreement with previous reports (Orsucci et al., 2008; Fan et al.,
2017; Tapodi et al., 2018), we found that PARP inhibition did
not affect the mitochondrial network morphology. Moreover,
PJ34 was found to preserve the mitochondrial network integrity
in B16F10 cells treated when combined with either cisplatin
or temozolomide.
One regulator of mitochondrial network dynamics is OPA1,
a large mitochondrial dynamin like GTPase that facilitates
fusion of mitochondria (Song et al., 2007). Although the
underlying mechanisms are still not fully understood, OPA1
exerts its fusion-promoting effects on mitochondria via the
tightly regulated equilibrium of long and short OPA1 isoforms
(Del Dotto et al., 2017). Oligomeric complexes made of the S- and
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L-OPA1 contribute to the preservation of the mitochondrial
cristae structures and, therefore, physiologic mitochondrial
morphology (Frezza et al., 2006). In response to various
stimuli, including collapsed membrane potential across the
inner mitochondrial membrane, depleted mitochondrial ATP
levels or pro-apoptotic signals, L-OPA1 is cleaved by proteases
like Yme1L and OMA1 (Song et al., 2007; Anand et al.,
2014) leading to the decomposition of OPA1 oligomers and
suppression of fused mitochondrial morphology (Duvezin-
Caubet et al., 2006; Ishihara et al., 2006; Guillery et al.,
2008; Ehses et al., 2009). Interestingly, in B16F10 cells
exposed to both PJ34 and the cytostatic agents examined,
we detected a disturbed equilibrium of the OPA1 isoforms
48 h post-treatment. However, although this correlates to the
onset of the cytotoxic effects of the combinatorial treatments,
dysregulation of the OPA equilibrium was not manifested in
corresponding morphological alterations of the mitochondrial
network. These data suggest that if OPA1 contributes to the
PJ34-augmented cytotoxic effects of cisplatin and temozolomide,
it is mediated independently of its function in the regulation
of mitochondrial morphology. Thus, whether the accumulation
of S-OPA1 plays a functional role in the potentiating effect of
pharmacologic PARP inhibition upon the use of alkylating agents
needs further investigations.
It is widely accepted that fragmentation of mitochondria
is a sign of cellular stress while fusion is usually present in
cells with balanced metabolic homeostasis. Interestingly, in our
experiments, the PJ34-mediated inhibition of mitochondrial
fission did not rescue cells from cell death suggesting
independent effects of PJ34 on viability and mitochondrial
morphology in B16F10 cells. This concept is, apparently,
supported by our observations that the PJ34-enhanced
cytotoxicity is not accompanied by the collapse of the
mitochondrial inner membrane potential, a hallmark of the
failure of mitochondrial metabolism. Moreover, by using a
dominant negative mutant PARP, we could also demonstrate that
reduction of the cellular PARylation, leads to hyperpolarization
in mitochondria, suggesting the existence of nuclear and
mitochondrial PARylation-dependent mechanisms with distinct
effects on cell survival.
Since the PJ34-facilitated cytotoxicity is preceded by
pro-survival mitochondrial effects like the maintained
mitochondrial fusion and elevated mitochondrial membrane
potential, one can also speculate that sustained mitochondrial
hyperpolarization results in mitochondrial damage through,
for instance, enhanced ROS production raising the question if
the observed accumulation of S-OPA1 is part of the clearance
of damaged mitochondria via a late-onset mitochondrial
fragmentation. This parallel with the attenuated DNA repair
might lead to the augmented cytotoxic capacity of cisplatin
and temozolomide.
CONCLUSION
Our data suggest that the dominant, long-term effect of
PARP inhibition when used in combination with alkylating
cytostatics is enhancement of DNA damage, likely, by reducing
repair activities. This synergism, eventually, supersedes the
parallel observed mitochondria-protecting effects of PARP
inhibition leading to increased nuclear fragmentation and
eventually cell death.
Our data suggest, however, that the PARP inhibition-
compromised DNA repair exacerbates the alkylating
compound-mediated accumulation of nuclear DNA damage
and nuclear fragmentation that, eventually, overcomes the
pro-survival mitochondrial effects (Figure 7). Our model
is in accordance with literature data on the overall effect
of PARP modulation that is, seemingly, determined by the
intricate relationship of the targeted molecular mechanisms
(Sukhanova et al., 2016; Hocsak et al., 2017). The diverse,
occasionally opposing effects of PARP inhibitors, even within
the same model, however, underlines the importance of
further, thorough evaluation of the use of these compounds in
human pathologies.
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